SecurityHVT / Haverty Furniture Companies, Inc. ()
Latest Market Date2018-05-18
Short Volume934
Market Volume 209,000
Short Percent 0%

Short Interest and Volume

HVT / Haverty Furniture Companies, Inc. short volume is shown in the following chart. Short Volume is a data set that can be used to understand investor sentiment. When an investor makes a short sale, they do so with the belief that a security will decline in price. If the short sale volume increases as a percentage of the total volume, then that suggests a bearish (negative) sentiment by the market. If short sale volume decreases as a percentage of total volume, then that suggests a bullish (positive) sentiment.

Short Volume
Total number of short shares traded on the major US markets each day
Short Percent
Total number of short shares traded divided by the total shares traded each day
Short Interest
Total number of open short positions of a security, divided by the total float (not shown)
Short Squeeze
When a company with a high degree of short interest increases in price, which forces short sellers to "cover" their short interest buy buying actual shares, which in turn drives the price up even further.

Note that Short Percent on this page is not the same as Short Interest. Short Interest is a measure of the number of open short positions of a security, divided by the total float. Short Percent is the daily short volume divided by the total volume. Short Interest is not available for this security at this time.

Market Date Total Volume Short Volume Short Percent
2018-05-18 209,000 934 0.45
2018-05-17 118,800 2,166 1.82
2018-05-16 94,400 1,058 1.12
2018-05-15 37,200 757 2.03
2018-05-14 120,600 601 0.50
2018-05-11 87,900 2,800 3.19
2018-05-10 121,000 611 0.50
2018-05-09 135,300 4,730 3.50
2018-05-08 126,400 2,990 2.37
2018-05-07 221,000 3,127 1.41

Related Articles

SGMO: Sangamo BioSciences Analysis and Research Report

2018-05-19 - Asif

OVERVIEW Sangamo BioSciences is a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients’ lives using its industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. Sangamo BioSciences is a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. Sangamo BioSciences has used its knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, Sangamo BioSciences has accrued signific...

HMNY: Helios and Matheson Analytics Analysis and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

BSTG: Biostage Analysis and Research Report

2018-05-17 - Asif

Overview Biostage is a biotechnology company developing bioengineered organ implants based on its novel CellframeTM technology. The company's Cellframe technology is comprised of a biocompatible scaffold that is seeded with the recipient’s own stem cells. This technology is being developed to treat life-threatening conditions of the esophagus, trachea or bronchus with the objective of dramatically improving the treatment paradigm for those patients. The company believe that its Cellframe technology will provide surgeons with new ways to address damage to the esophagus, bronchus, and trachea due to congenital abnormalities, cancer, infection or trauma. Products being developed based on its Cellframe technology for those indications are called CellspanTM products. The company announced favorable preliminary pre-clinical results of large-animal studies for the esophagus, trachea and bronchus in November 2015. Since then, the Cellspan esophageal implant product candidates hav...